Comment on 'Impact of CYP2D6* 10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy'

Cancer Science

Volumn 99, Issue 8, 2008, Pages 1706-1707

  Lash, Timothy L ^a,b,c   Ahern, Thomas P ^a   Cronin Fenton, Deirdre ^b   Garne, Jens Peter ^d   Hamilton Dutoit, Stephen ^b   Sørensen, Henrik Toft ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; AMINO ACID SUBSTITUTION; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; ENZYME ACTIVITY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE FUNCTION; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; NOTE; PHARMACOGENOMICS; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RECURRENCE RISK; RECURRENT CANCER;

ALLELES; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYTOCHROME P-450 CYP2D6; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; NEOPLASM RECURRENCE, LOCAL; TAMOXIFEN;

EID: 49749142641     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00864.x     Document Type: Note

References (10)

1. Kiyotani K, Mushiroda T, Sasa M et al. Impact of CYP2D6* 10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008. doi: 10.1111/ j.1349-2008.7006.00780.x.
2. Jin Y, Desta Z, Ward B et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30-9.
3. Rothman KJ, Greenland S. Cohort studies. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2008; 100-10.
4. Glymour MM, Greenland S. Causal diagrams. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2008; 183-212.
5. Lash TL, Ahern TP, Cronin-Fenton D et al. Modification of tamoxifen response: What have we learned? J Clin Oncol 2008; 26: 1764-5.
6. Myrand S, Sekiguchi K, Man M et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: Comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 2008; doi: 10.1038/ sj.clpt.6100482.
7. Curtis E, Quale C, Haggstrom D, Smith-Bindman R. Racial and ethnic differences in breast cancer survival. Cancer 2008; 112: 171-80.
8. Enger SM, Thwin SS, Buist DS et al. Breast cancer treatment of older women in integrated health care settings. J Clin Oncol 2006; 24: 4377-83.
9. Tada K, Yoshimoto M, Nishimura S et al. Comparison of two-year and five-year tamoxifen use in Japanese post-menopausal women. Eur J Surg Oncol 2004; 30: 1077-83.
10. Early Breast Cancer Trialists'Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005; 365: 1687-717.